A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation.

Trial Profile

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2012

At a glance

  • Drugs Nicotine abuse vaccine (Primary)
  • Indications Smoking withdrawal; Substance-related disorders
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 08 May 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 08 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jul 2011 Primary endpoint 'Clinical-response' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top